Topics:
Radiation Oncology • Neuro-Oncology
How are the long term results of RTOG 9802 being incorporated into practice in the treatment of "high risk" low grade gliomas?
The long term data indicating an OS and PFS benefit with the addition PCV with RT when compared to RT alone were reported in a NCI press release (http://www.cancer.gov/newscenter/newsfromnci/2014/RTOG9802) and at ASCO/ASTRO (http://meetinglibrary.asco.org/content/127483-144). How are insitutions incorporating this data into their treatment recommendations at this time? Any insight yet on treatment benefit in certain molecular subtypes (i.e. 1p19q codeletion or IDH1 mutation)?
Answer from: Radiation Oncologist at Academic Institution
Answer was written along with Cleveland Clinic resident, Ehsan Balagamwala, MDThe decision to treat low grade gliomas (LGG) can be very challenging. At our institution, we typically utilize the EORTC risk factors to stratify our patients. EORTC high risk is defined as having 3 or more of the followi...
Sign in or Register to read more